Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2C | Q14957 | 3/20 | 0.55 |
| ▸ | PDE4B | Q07343 | 7/20 | 0.50 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 3/20 | 0.46 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.46 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.46 |
| ▸ | MAPK7 | Q13164 | 2/20 | 0.45 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4414665 | 0.90 | GRIN2C (0.64) | GRIN2CMEN1KMT2ATP53MTNR1B | |
| SCHEMBL4418256 | 0.84 | KMT2A (0.52) | GRIN2CPDE4BPDE4DMEN1KMT2A | |
| SCHEMBL4415216 | 0.83 | GRIN2C (0.55) | GRIN2CPDE4BPDE4DMEN1KMT2A | |
| SCHEMBL4413447 | 0.82 | KMT2A (0.55) | GRIN2CPDE4BPDE4DMEN1KMT2A | |
| SCHEMBL13973152 | 0.78 | PDE4B (0.62) | PDE4BPDE4DMEN1KMT2AMAPK7 | |
| SCHEMBL4423047 | 0.77 | GRIN2C (0.51) | GRIN2CMEN1KMT2AMAPK7MTNR1B | |
| SCHEMBL4416192 | 0.76 | GRIN2C (0.47) | GRIN2CMEN1KMT2AMAPK7MTNR1B | |
| SCHEMBL4412546 | 0.76 | GRIN2C (0.49) | GRIN2CMEN1KMT2ATP53MAPK7 | |
| SCHEMBL4413378 | 0.76 | KMT2A (0.45) | GRIN2CMEN1KMT2AMTNR1B | |
| SCHEMBL4424375 | 0.75 | HTT (0.71) | GRIN2CKMT2AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1663983-B1 | N-SUBSTITUTED, 6,8-DIALKOXY-1,2,3,4-TETRAHYDRO-1H-ISOQUINOLINE AS POTASSIUM CHANNELS MODULATORS | 4SC AG (DE) | 2009-01-21 | — | — | EP | disclosed |
| US-20050070570-A1 | Novel potassium channels modulators | 4SC AG (DE) | 2005-03-31 | — | — | US | disclosed |
| EP-1489071-A1 | N-substituted, 3,4-dihydro-1H-isoquinoline as potassium channels modulators | 4SC AG (DE) | 2004-12-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070570-A1 | Novel potassium channels modulators | HCN4, KCNA4, KCNN4 | GRIN2C 567/4885PDE4B 1553/4885PDE4D 1906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.